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The FOGT (Study Group for GI-Oncology) was formed
among clinicians and scientists with the aim of testing
innovative scientific concepts in gastrointestinal tumors,
especially colorectal cancers, within controlled clinical
studies.
In the FOGT-1 trial (n=813stage III or II(T4N0) colon
cancer patients) the effect on recurrence-free and overall
survivalwas tested by an adjuvant chemotherapy proto-
col with double-modulation of 5-fluorouracil (5-FU) and
levamisole (LEV) with either folinic acid (FA) or inter-
feron-alpha (IFNa) in a three arm randomized trial
within 60 German cancer centers. In parallel, in the
FOGT-2 trial stage II or III rectal cancer patients (n =
796 pts.) were treated with additional postoperative
radiochemotherapy (50,4 Gy). The most effective arm of
these trials was tested as control arm versus a 5-FU/FA/
irinotecan (FOLFIRI) protocol in the two-arm FOGT-4
trial (n = 281stage III or II(T4N0) colon cancer pts.) for
adjuvant therapy in colon cancer.
In the FOGT-1 trial, we found a 11% overall survival
(OAS) benefit in patients who were treated for one year
adjuvantly with 5-FU plus FA (77% OAS), compared to
treatment with either 5-FU or 5-FU plus interferon-
alpha (each 66% OAS). This effect was statistically sig-
nificant for colon cancer patients (FOGT-1), but not for
rectal cancer patients (FOGT-2). In rectal cancer, the
5-FU plus FA arm showed this effect with a 12% survi-
val benefit only in the stage II subgroup. The FA modu-
lation of 5-FU was safe and cost-effective. The
modulation with IFNa was less effective and caused
more toxicity, mainly diarrhea in rectal cancer patients.
When the 5FU/FA protocol was slightly modulated
(treatment for 6 months, no LEV) and compared to the
FOLFIRI protocol (FOGT-4), survival and toxicity in the
5FU/FA arm was similar to the toxicity observed in the
earlier studies, and the FOLFIRI arm was significantly
more toxic (40% vs. 14% grade III/IV toxicity) without
any benefit in recurrence rates (25% vs. 23% local/sys-
temic recurrence) or survival. The FOGT-4 study con-
firms three other studies that – in contrast to palliative
treatment protocols – did not find any benefit for the
role of irinotecan in the adjuvant treatment of colon
cancer.
In conclusion, by conducting the three FOGT-studies
with more than 1800 patients, we identified a safe and
effective treatment protocol for adjuvant therapy in
colon cancer, consisting of infusional 5-fluorouracil and
folinic acid, given for at least six months, and well com-
binable with additional postoperative radiotherapy. This
protocol was not improved by addition of irinotecan in
colon cancer patients.
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